Meeting
2015 Gastrointestinal Cancers Symposium
Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance).
Authors
Jeffrey Melson Clarke
Duke University, Durham, NC
Jeffrey Melson Clarke , Herbert Pang , Mark D. Starr , Ace Joseph Hatch , Hedy Lee Kindler , Eileen Mary O'Reilly , Federico Innocenti , Alan P. Venook , Herbert Hurwitz , Andrew B. Nixon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 306)
DOI
10.1200/jco.2015.33.3_suppl.306
Abstract #
306
Poster Bd #
B27
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Baseline albumin (b-alb) as a potential predictive biomarker for the efficacy of bevacizumab (B) therapy (tx) in patients (pts) with advanced pancreas cancer (APCA): A comparative analysis.
First Author: Ludmila Katherine Martin
Poster
2022 ASCO Annual Meeting
Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.
First Author: Tara Elisabeth Seery
Poster
2021 Gastrointestinal Cancers Symposium
Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC).
First Author: Hiromichi Shirasu
Poster
2017 ASCO Annual Meeting
TAS-118 (S-1 plus leucovorin) versus S-1 in gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, phase III trial (GRAPE trial).
First Author: Makoto Ueno